Inhibition of hyaluronic acid synthesis suppresses angiogenesis in developing endometriotic lesions

PLoS ONE

Volumn 11, Issue 3, 2016, Pages

  Olivares, Carla N ^a   Alaniz, Laura D ^b   Menger, Michael D ^c   Barañao, Rosa I ^a   Laschke, Matthias W ^c   Meresman, Gabriela F ^a  

^a INST DE BIOL Y MED EXPERIMENTAL   (Argentina)

^b Universidad Nacional del Noroeste de la Provincia de Buenos Aires   (Argentina)

^c SAARLAND UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CD31 ANTIGEN; HERMES ANTIGEN; HYALURONIC ACID; HYMECROMONE; LACTATE DEHYDROGENASE; SODIUM CHLORIDE; ANGIOGENESIS INHIBITOR; CYCLINE;

ADULT; ANGIOGENESIS; ANIMAL EXPERIMENT; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; CAPILLARY DENSITY; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; ENDOMETRIOSIS; ENDOTHELIUM CELL; FEMALE; FLUORESCENCE MICROSCOPY; HISTOLOGY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LONG TERM SURVIVAL; MALE; MOUSE; NONHUMAN; RAT; SKINFOLD; VASCULAR RING; VASCULARIZATION; ANIMAL; ANTAGONISTS AND INHIBITORS; AORTA; BAGG ALBINO MOUSE; DRUG EFFECTS; ENDOMETRIUM; METABOLISM; MICROVASCULATURE; PATHOLOGY; SPRAGUE DAWLEY RAT; TRANSPLANTATION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIGENS, CD31; AORTA; APOPTOSIS; CASPASE 3; CELL PROLIFERATION; DOWN-REGULATION; ENDOMETRIOSIS; ENDOMETRIUM; FEMALE; HYALURONIC ACID; HYMECROMONE; MALE; MICE; MICE, INBRED BALB C; MICROVESSELS; NEOVASCULARIZATION, PHYSIOLOGIC; PROLIFERATING CELL NUCLEAR ANTIGEN; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84962187927     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0152302     Document Type: Article

References (51)

1. Giudice LC. Clinical practice. Endometriosis. N Engl J Med. 2010;362:2389-2398.
2. Burney RO, Giudice LC. Pathogenesis and pathophysiology of endometriosis. Fertil Steril. 2012;98:511-519. doi: 10.1016/j.fertnstert.2012.06.029 PMID: 22819144
3. Sampson JA. Peritoneal endometriosis due to menstrual dissemination of endometrial tissue into the peritoneal cavity. Am J Obstet Gynecol. 1927;14:422-469.
4. Angioni S, Cofelice V, Pontis A, Tinelli R, Socolov R. New trends of progestins treatment of endometriosis. Gynecol Endocrinol. 2014;30:769-773. doi: 10.3109/09513590.2014.950646 PMID: 25144122
5. Soares SR, Martinez-Varea A, Hidalgo-Mora JJ, Pellicer A. Pharmacologic therapies in endometriosis: a systematic review. Fertil Steril. 2012;98:529-555. doi: 10.1016/j.fertnstert.2012.07.1120 PMID: 22938768
6. Laschke MW, Menger MD. Anti-angiogenic treatment strategies for the therapy of endometriosis. Hum Reprod Update. 2012;18:682-702. doi: 10.1093/humupd/dms026 PMID: 22718320
7. Platteeuw L, D'Hooghe T. Novel agents for the medical treatment of endometriosis. Curr Opin Obstet Gynecol. 2014;26:243-252.
8. Dechaud H, Witz CA, Montoya-Rodriguez IA, Degraffenreid LA, Schenken RS. Mesothelial cell-associated hyaluronic acid promotes adhesion of endometrial cells to mesothelium. Fertil Steril. 2001;76:1012-1018. PMID: 11704126
9. Griffith JS, Liu YG, Tekmal RR, Binkley PA, Holden AE, Schenken RS. Menstrual endometrial cells from women with endometriosis demonstrate increased adherence to peritoneal cells and increased expression of CD44 splice variants. Fertil Steril. 2010;93:1745-1749. doi: 10.1016/j.fertnstert.2008. 12.012 PMID: 19200980
10. Hasegawa A, Yoshino O, Osuga Y, Hirata T, Yano T, Taketani Y. High soluble CD44 concentration in peritoneal fluid in endometriosis. Fertil Steril. 2008;89:1267-1268. PMID: 17919613
11. Ponta H, Sherman L, Herrlich PA. CD44: from adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol. 2003;4:33-45. PMID: 12511867
12. Adamia S, Maxwell CA, Pilarski LM. Hyaluronan and hyaluronan synthases: potential therapeutic targets in cancer. Curr Drug Targets Cardiovasc Haematol Disord. 2005;5:3-14. PMID: 15720220
13. West DC, Hampson IN, Arnold F, Kumar S. Angiogenesis induced by degradation products of hyaluronic acid. Science. 1985;228:1324-1326. PMID: 2408340
14. West DC, Kumar S. Hyaluronan and angiogenesis. Ciba Found Symp. 1989;143:187-201. PMID: 2478344
15. Nykopp TK, Rilla K, Tammi MI, Tammi RH, Sironen R, Hamalainen K et al. Hyaluronan synthases (HAS1-3) and hyaluronidases (HYAL1-2) in the accumulation of hyaluronan in endometrioid endometrial carcinoma. BMC Cancer. 2010;10:512-doi: 10.1186/1471-2407-10-512 PMID: 20875124
16. Afify AM, Craig S, Paulino AF, Stern R. Expression of hyaluronic acid and its receptors, CD44s and CD44v6, in normal, hyperplastic, and neoplastic endometrium. Ann Diagn Pathol. 2005;9:312-318. PMID: 16308159
17. Hasegawa A, Yoshino O, Osuga Y, Kodama A, Takamura M, Nishii O et al. Hyaluronic acid reagent suppressed endometriotic lesion formation in a mouse model. Fertil Steril. 2010;93:2757-2759. doi: 10.1016/j.fertnstert.2010.02.053 PMID: 20356589
18. Kultti A, Pasonen-Seppanen S, Jauhiainen M, Rilla KJ, Karna R, Pyoria E et al. 4-Methylumbelliferone inhibits hyaluronan synthesis by depletion of cellular UDP-glucuronic acid and downregulation of hyaluronan synthase 2 and 3. Exp Cell Res. 2009;315:1914-1923. doi: 10.1016/j.yexcr.2009.03.002 PMID: 19285976
19. Takeda S, Aburada M. The choleretic mechanism of coumarin compounds and phenolic compounds. J Pharmacobiodyn. 1981;4:724-734. PMID: 7334456
20. Fontaine L, Grand M, Molho D, Chabert MJ, Boschetti E. [Choleretic, spasmolytic and general pharmacologic activities of 4-methylumbelliferone]. Therapie. 1968;23:51-62. PMID: 5671530
21. Lokeshwar VB, Lopez LE, Munoz D, Chi A, Shirodkar SP, Lokeshwar SD et al. Antitumor activity of hyaluronic acid synthesis inhibitor 4-methylumbelliferone in prostate cancer cells. Cancer Res. 2010;70:2613-2623. doi: 10.1158/0008-5472. CAN-09-3185 PMID: 20332231
22. Twarock S, Freudenberger T, Poscher E, Dai G, Jannasch K, Dullin C et al. Inhibition of oesophageal squamous cell carcinoma progression by in vivo targeting of hyaluronan synthesis. Mol Cancer. 2011;10:30-doi: 10.1186/1476-4598-10-30 PMID: 21429221
23. Urakawa H, Nishida Y, Wasa J, Arai E, Zhuo L, Kimata K et al. Inhibition of hyaluronan synthesis in breast cancer cells by 4-methylumbelliferone suppresses tumorigenicity in vitro and metastatic lesions of bone in vivo. Int J Cancer. 2012;130:454-466. doi: 10.1002/ijc.26014 PMID: 21387290
24. Piccioni F, Malvicini M, Garcia MG, Rodriguez A, Atorrasagasti C, Kippes N et al. Antitumor effects of hyaluronic acid inhibitor 4-methylumbelliferone in an orthotopic hepatocellular carcinoma model in mice. Glycobiology. 2012;22:400-410. doi: 10.1093/glycob/cwr158 PMID: 22038477
25. Garcia-Vilas JA, Quesada AR, Medina MA. 4-methylumbelliferone inhibits angiogenesis in vitro and in vivo. J Agric Food Chem. 2013;61:4063-4071. doi: 10.1021/jf303062h PMID: 23581646
26. Byers SL, Wiles MV, Dunn SL, Taft RA. Mouse estrous cycle identification tool and images. PLoS One. 2012;7:e35538-doi: 10.1371/journal.pone.0035538 PMID: 22514749
27. Laschke MW, Elitzsch A, Vollmar B, Menger MD. In vivo analysis of angiogenesis in endometriosis-like lesions by intravital fluorescence microscopy. Fertil Steril. 2005;84:1199-1209. PMID: 16210012
28. Laschke MW, Vollmar B, Menger MD. The dorsal skinfold chamber: window into the dynamic interaction of biomaterials with their surrounding host tissue. Eur Cell Mater. 2011;22:147-164. PMID: 21932192
29. Feng D, Welker S, Korbel C, Rudzitis-Auth J, Menger MD, Montenarh M et al. Protein kinase CK2 is a regulator of angiogenesis in endometriotic lesions. Angiogenesis. 2012;15:243-252. doi: 10.1007/s10456-012-9256-2 PMID: 22354315
30. Feng D, Menger MD, Wang H, Laschke MW. Luminal epithelium in endometrial fragments affects their vascularization, growth and morphological development into endometriosis-like lesions in mice. Dis Model Mech. 2014;7:225-232. doi: 10.1242/dmm.013664 PMID: 24291760
31. Nenicu A, Korbel C, Gu Y, Menger MD, Laschke MW. Combined blockade of angiotensin II type 1 receptor and activation of peroxisome proliferator-activated receptor-gamma by telmisartan effectively inhibits vascularization and growth of murine endometriosis-like lesions. Hum Reprod. 2014;29:1011-1024. doi: 10.1093/humrep/deu035 PMID: 24578472
32. Ehrmantraut S, Laschke MW, Merkel D, Scheuer C, Willnecker V, Meyer-Lindenberg A et al. Perioperative steroid administration inhibits angiogenic host tissue response to porous polyethylene (Medpor) implants. Eur Cell Mater. 2010;19:107-116. PMID: 20186670
33. Gu Y, Scheuer C, Feng D, Menger MD, Laschke MW. Inhibition of angiogenesis: a novel antitumor mechanism of the herbal compound arctigenin. Anticancer Drugs. 2013;24:781-791. doi: 10.1097/CAD.0b013e328362fb84 PMID: 23744558
34. Saegusa M, Hashimura M, Okayasu I. CD44 expression in normal, hyperplastic, and malignant endometrium. J Pathol. 1998;184:297-306. PMID: 9614383
35. Murphy JF, Lennon F, Steele C, Kelleher D, Fitzgerald D, Long AC. Engagement of CD44 modulates cyclooxygenase induction, VEGF generation, and proliferation in human vascular endothelial cells. FASEB J. 2005;19:446-448. PMID: 15640281
36. Vigetti D, Karousou E, Viola M, Deleonibus S, De LG, Passi A. Hyaluronan: biosynthesis and signaling. Biochim Biophys Acta. 2014;1840:2452-2459. doi: 10.1016/j.bbagen. 2014.02.001 PMID: 24513306
37. Olivares C, Bilotas M, Buquet R, Borghi M, Sueldo C, Tesone M et al. Effects of a selective cyclooxygenase-2 inhibitor on endometrial epithelial cells from patients with endometriosis. Hum Reprod. 2008;23:2701-2708. doi: 10.1093/humrep/den315 PMID: 18716040
38. Olivares C, Ricci A, Bilotas M, Baranao RI, Meresman G. The inhibitory effect of celecoxib and rosiglitazone on experimental endometriosis. Fertil Steril. 2011;96:428-433. doi: 10.1016/j.fertnstert.2011.05. 063 PMID: 21683949
39. Arai E, Nishida Y, Wasa J, Urakawa H, Zhuo L, Kimata K et al. Inhibition of hyaluronan retention by 4-methylumbelliferone suppresses osteosarcoma cells in vitro and lung metastasis in vivo. Br J Cancer. 2011;105:1839-1849. doi: 10.1038/bjc.2011.459 PMID: 22045192
40. Yoshioka Y, Kozawa E, Urakawa H, Arai E, Futamura N, Zhuo L et al. Suppression of hyaluronan synthesis alleviates inflammatory responses in murine arthritis and in human rheumatoid synovial fibroblasts. Arthritis Rheum. 2013;65:1160-1170. doi: 10.1002/art.37861 PMID: 23335273
41. Laschke MW, Menger MD. In vitro and in vivo approaches to study angiogenesis in the pathophysiology and therapy of endometriosis. Hum Reprod Update. 2007;13:331-342. PMID: 17347159
42. Colton CK. Implantable biohybrid artificial organs. Cell Transplant. 1995;4:415-436. PMID: 7582573
43. Folkman J, Hochberg M. Self-regulation of growth in three dimensions. J Exp Med. 1973;138:745-753. PMID: 4744009
44. Svensson A, Backman U, Fuchs D, Christofferson R, Azarbayjani F. Angiogenesis can be reduced without significant reduction of tumor growth. Anticancer Res. 2007;27:3883-3889. PMID: 18225546
45. Laschke MW, Elitzsch A, Scheuer C, Holstein JH, Vollmar B, Menger MD. Rapamycin induces regression of endometriotic lesions by inhibiting neovascularization and cell proliferation. Br J Pharmacol. 2006;149:137-144. PMID: 16894343
46. Laschke MW, Elitzsch A, Scheuer C, Vollmar B, Menger MD. Selective cyclo-oxygenase-2 inhibition induces regression of autologous endometrial grafts by down-regulation of vascular endothelial growth factor-mediated angiogenesis and stimulation of caspase-3-dependent apoptosis. Fertil Steril. 2007;87:163-171. PMID: 17081538
47. Laschke MW, Schwender C, Scheuer C, Vollmar B, Menger MD. Epigallocatechin-3-gallate inhibits estrogen-induced activation of endometrial cells in vitro and causes regression of endometriotic lesions in vivo. Hum Reprod. 2008;23:2308-2318. doi: 10.1093/humrep/den245 PMID: 18603648
48. Benitez A, Yates TJ, Shamaldevi N, Bowen T, Lokeshwar VB. Dietary supplement hymecromone and sorafenib: a novel combination for the control of renal cell carcinoma. J Urol. 2013;190:285-290. doi: 10.1016/j.juro.2012.12.011 PMID: 23228386
49. Uchakina ON, Ban H, McKallip RJ. Targeting hyaluronic acid production for the treatment of leukemia: treatment with 4-methylumbelliferone leads to induction of MAPK-mediated apoptosis in K562 leukemia. Leuk Res. 2013;37:1294-1301. doi: 10.1016/j.leukres.2013.07.009 PMID: 23876826
50. Zhao YW, Jin L, Li ZM, Zhao CJ, Wei YQ, Yang HS. Enhanced antitumor efficacy by blocking activation of the phosphatidylinositol 3-kinase/Akt pathway during anti-angiogenesis therapy. Cancer Sci. 2011;102:1469-1475. doi: 10.1111/j.1349-7006.2011.01979.x PMID: 21561530
51. Bello L, Carrabba G, Giussani C, Lucini V, Cerutti F, Scaglione F et al. Low-dose chemotherapy combined with an antiangiogenic drug reduces human glioma growth in vivo. Cancer Res. 2001;61:7501-7506. PMID: 11606386